Lymphoma, B-Cell: all 1,415 studies
Page 13 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.
- 131I-rituximab for Relapsed or Refractory Marginal Zone B-cell LymphomaStatus unknownNCT01678404Phase 2
- A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)Status unknownNCT01676558Phase 2
- Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.Status unknownNCT01670370Phase 2
- BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and HematologyCompletedNCT01660776
- GA In NEwly Diagnosed Diffuse Large B Cell LymphomaTerminatedNCT01659099Phase 3
- Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01658319Phase 1
- STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell LymphomaStatus unknownNCT01653067Phase 2
- Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWithdrawnNCT01652014Phase 2
- Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT01647971Phase 1/2
- Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell LymphomaCompletedNCT01622439Phase 1/2
- Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell LymphomaCompletedNCT01606605
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell LymphomaCompletedNCT01582776Phase 1/2
- A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin LymphomaCompletedNCT01569750Phase 1
- Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaCompletedNCT01567709Phase 1
- Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second RelapseCompletedNCT01562990Phase 1/2
- Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
- Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV)Status unknownNCT01545544
- Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence TrialTerminatedNCT01534949Phase 1
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid MalignanciesCompletedNCT01523223Phase 1
- Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk PatientsCompletedNCT01516580Phase 3
- Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)CompletedNCT01502982Phase 2
- Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
- Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma PatientsCompletedNCT01481272Phase 2
- OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal VincristineCompletedNCT01478542Phase 3
- Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline RegimenCompletedNCT01478269
- SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) PatientsCompletedNCT01472887Phase 2
- Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT01471210Phase 1
- Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT01470456Phase 2
- Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell LymphomaTerminatedNCT01466868Phase 2
- A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic CancersCompletedNCT01460134Phase 1
- Study in Patients With Primary Breast Diffuse Large B-cell LymphomaCompletedNCT01448096Phase 2
- Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)Status unknownNCT01435720Phase 1/2
- A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)WithdrawnNCT01423539Phase 2
- MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell LymphomaWithdrawnNCT01415765Phase 1/2
- Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell LymphomaTerminatedNCT01402440Phase 1
- Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell LymphomaCompletedNCT01361191Phase 2
- Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and LymphomaTerminatedNCT01352312Phase 1
- Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaCompletedNCT01351935Phase 1
- An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular LymphomaCompletedNCT01340443
- A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins LymphomaCompletedNCT01290549Phase 1
- Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)CompletedNCT01284192Phase 1
- Abbreviated R-CHOP in Completely Excised Stage I or II DLBCLStatus unknownNCT01279902Phase 2
- R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell LymphomaStatus unknownNCT01278602Phase 2
- The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT01266668
- Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell LymphomasWithdrawnNCT01263418Phase 2
- Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
- Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin LymphomaCompletedNCT01239875Early Phase 1
- A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT01238692Phase 2
- Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnNCT01238146Phase 1/2
- Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell LymphomaCompletedNCT01226849Phase 1
- A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's LymphomaCompletedNCT01209130Phase 1
- Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell LymphomaCompletedNCT01202448Not applicable
- Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 YearsCompletedNCT01195714Phase 2
- Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell LymphomaStatus unknownNCT01181999Phase 2
- Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell LymphomaStatus unknownNCT01178645Phase 2
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)CompletedNCT01164267Phase 2
- RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsCompletedNCT01158274Phase 1
- 90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell LymphomaCompletedNCT01157988Phase 2
- R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCLCompletedNCT01148446Phase 3
- Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple MyelomaCompletedNCT01148108Phase 2
- AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or LymphomaCompletedNCT01129193Phase 1
- Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOPCompletedNCT01122472Phase 3
- Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTerminatedNCT01116154Phase 1
- Mini-CHOP and Rituximab in Patients Aged Over 80 YearsCompletedNCT01087424Phase 2
- Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell TransplantationCompletedNCT01087294Phase 1
- Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)CompletedNCT01068392Phase 2
- DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell LymphomaStatus unknownNCT01066429Phase 2
- Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT01054781Phase 2
- Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
- Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT01045928Phase 1
- Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe FatigueWithdrawnNCT01044004Not applicable
- Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's LymphomaStatus unknownNCT01009970Phase 2
- Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin LymphomaCompletedNCT01000753
- Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1CompletedNCT00968656Phase 1
- Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT00968331Phase 2
- High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell LymphomaCompletedNCT00965289Phase 2
- Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)CompletedNCT00944905Phase 1
- A Clinico-Pathologic Study of Primary Mediastinal B-Cell LymphomaCompletedNCT00944567
- Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or LeukemiaTerminatedNCT00933985Phase 1
- Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)Status unknownNCT00927797Phase 2
- Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell LymphomaTerminatedNCT00906841Phase 2
- Zevalin Twice in Aggressive Non-Hodgkin LymphomaTerminatedNCT00902525Phase 2
- Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT00891072Phase 1
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) TherapyCompletedNCT00850512Phase 2
- Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell LymphomaCompletedNCT00849654Phase 1
- Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) PatientsStatus unknownNCT00846157Phase 3
- Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive LymphomasCompletedNCT00842595Phase 2
- Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT00836173Phase 2
- Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell LymphomaCompletedNCT00834951Phase 2
- Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT00831597Phase 2
- Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
- SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's LymphomaCompletedNCT00796731Phase 1
- A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's LymphomaCompletedNCT00794638Phase 1
- R-CHOP-B Bevacizumab for Diffuse Large B Cell LymphomaTerminatedNCT00788606Phase 2
- GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT00776802Phase 1/2
- FAU in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00769288Phase 1
- A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell LymphomasTerminatedNCT00768339Phase 1/2